MA28155A1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number
MA28155A1
MA28155A1 MA29019A MA29019A MA28155A1 MA 28155 A1 MA28155 A1 MA 28155A1 MA 29019 A MA29019 A MA 29019A MA 29019 A MA29019 A MA 29019A MA 28155 A1 MA28155 A1 MA 28155A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
microparticles
biocompatible
somatostanine
pharmaceutical compositions
Prior art date
Application number
MA29019A
Other languages
English (en)
Inventor
Markus Ahlheim
Michael Ausborn
Olivier Lambert
Marc Riemenschnitter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28155A1 publication Critical patent/MA28155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne des microparticules comprenant un analogue de somatostanine incorporé dans une matrice polymère biocompatible pharmaceutiquement acceptable à libération prolongée et des compositions pharmaceutiques comprenant lesdites microparticules.
MA29019A 2003-11-14 2006-05-11 Composition pharmaceutique MA28155A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds

Publications (1)

Publication Number Publication Date
MA28155A1 true MA28155A1 (fr) 2006-09-01

Family

ID=34593737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29019A MA28155A1 (fr) 2003-11-14 2006-05-11 Composition pharmaceutique

Country Status (30)

Country Link
US (3) US7759308B2 (fr)
EP (1) EP1686964B9 (fr)
JP (1) JP4682145B2 (fr)
KR (1) KR101233892B1 (fr)
AR (1) AR047310A1 (fr)
AT (1) ATE455537T1 (fr)
AU (1) AU2004289055C1 (fr)
BR (1) BRPI0416227B8 (fr)
CA (1) CA2541944C (fr)
CY (2) CY1110293T1 (fr)
DE (1) DE602004025271D1 (fr)
DK (1) DK1686964T3 (fr)
EC (1) ECSP066565A (fr)
ES (1) ES2339026T3 (fr)
HR (1) HRP20100190T1 (fr)
IL (1) IL175286A (fr)
IS (1) IS8480A (fr)
LU (1) LU92701I2 (fr)
MA (1) MA28155A1 (fr)
MX (1) MXPA06005357A (fr)
MY (1) MY158342A (fr)
NO (2) NO337172B1 (fr)
NZ (1) NZ546788A (fr)
PE (1) PE20050581A1 (fr)
PL (1) PL1686964T3 (fr)
PT (1) PT1686964E (fr)
RU (1) RU2404749C2 (fr)
SI (1) SI1686964T1 (fr)
TW (1) TWI295178B (fr)
WO (1) WO2005046645A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
ES2755032T3 (es) * 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
EP2167039B1 (fr) * 2007-05-18 2016-09-28 Durect Corporation Formulations à dépôt amélioré
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
KR101921800B1 (ko) * 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
CA2716010C (fr) 2008-04-03 2019-10-01 Zymogenetics, Inc. Microspheres hemostatiques
WO2010003939A1 (fr) 2008-07-08 2010-01-14 Novartis Ag Utilisation de pasiréotide pour le traitement d'une hypoglycémie hyperinsulinémique endogène
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
WO2010123574A1 (fr) 2009-04-23 2010-10-28 Atrp Solutions Inc Macromolécules en étoile pour soins d'hygiène personnelle et soins domestiques
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (fr) 2012-03-07 2013-09-12 Novartis Ag Nouvelle application pour la pasireotide
CN105189643B (zh) 2012-08-30 2019-01-15 派诺聚合物技术公司 用于水力压裂液的双重机制增稠剂
EP2951220B1 (fr) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Macromolécules en étoile tolérantes aux sels
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
CN107075015B (zh) 2014-07-03 2019-08-23 派诺聚合物技术公司 表面活性剂-相容性星形大分子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1998032423A1 (fr) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Microspheres a liberation prolongee, leur production et utilisation
WO2000004916A1 (fr) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation de peptides hydrosolubles
PT1098660E (pt) * 1998-07-23 2003-02-28 Conseil De Rech D Appl Sci S C Encapsulacao de peptidos soluveis em agua
EP1240896A3 (fr) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation de peptides hydrosolubles
AU767837B2 (en) 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20050152980A1 (en) * 2002-03-13 2005-07-14 Michael Ausborn Pharmeutical microparticles
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
WO2005046645A1 (fr) 2005-05-26
AU2004289055B2 (en) 2008-10-30
LU92701I2 (fr) 2015-11-02
BRPI0416227A (pt) 2007-01-02
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
US8188037B2 (en) 2012-05-29
CY2015011I1 (el) 2016-04-13
DK1686964T3 (da) 2010-05-17
BRPI0416227B1 (pt) 2019-06-18
ATE455537T1 (de) 2010-02-15
NO2016003I2 (no) 2016-02-02
SI1686964T1 (sl) 2010-05-31
JP2007511482A (ja) 2007-05-10
EP1686964B9 (fr) 2010-08-04
CA2541944C (fr) 2014-02-25
RU2006120484A (ru) 2007-12-27
NO20062777L (no) 2006-08-14
AU2004289055C1 (en) 2009-05-21
DE602004025271D1 (de) 2010-03-11
US20120214749A1 (en) 2012-08-23
US20100272809A1 (en) 2010-10-28
TWI295178B (en) 2008-04-01
MXPA06005357A (es) 2006-07-10
PT1686964E (pt) 2010-02-04
IL175286A0 (en) 2006-09-05
KR101233892B1 (ko) 2013-02-18
IS8480A (is) 2006-05-23
PE20050581A1 (es) 2005-09-09
AR047310A1 (es) 2006-01-18
HK1093682A1 (en) 2007-03-09
RU2404749C2 (ru) 2010-11-27
NO2016003I1 (no) 2016-02-02
MY158342A (en) 2016-09-30
CY2015011I2 (el) 2016-04-13
TW200529883A (en) 2005-09-16
PL1686964T3 (pl) 2010-06-30
KR20060115873A (ko) 2006-11-10
NO337172B1 (no) 2016-02-01
CA2541944A1 (fr) 2005-05-26
EP1686964A1 (fr) 2006-08-09
IL175286A (en) 2012-05-31
ES2339026T3 (es) 2010-05-14
JP4682145B2 (ja) 2011-05-11
EP1686964B1 (fr) 2010-01-20
BRPI0416227B8 (pt) 2021-05-25
CY1110293T1 (el) 2015-01-14
US20070212418A1 (en) 2007-09-13
ECSP066565A (es) 2006-10-17
NZ546788A (en) 2009-12-24
US7759308B2 (en) 2010-07-20

Similar Documents

Publication Publication Date Title
MA28155A1 (fr) Composition pharmaceutique
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
FR2856301B1 (fr) Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
DE60318446D1 (de) Nichtpolymere lipophile pharmazeutische implantat-zusammensetzungen für die intraokulare anwendung
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
EP1790340A3 (fr) Chimotherapie combinée
FR2862540B1 (fr) Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MA28844B1 (fr) Composition pharmaceutique comprenant de la drospirenone et de l'ethynylestradiol
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
MY167123A (en) Conveniently implantable sustained release drug compositions
BRPI0013439B1 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
WO2003028653A3 (fr) Compositions pharmaceutiques a liberation prolongee
CA2583764A1 (fr) Composes et methodes visant a reguler l'activite de la thrombopoietine
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
BRPI0412458A (pt) composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
ITMI20021725A1 (it) Composizioni farmaceutiche ad attivita' antibiotica.
BE1014502A5 (fr) Compositions pharmaceutiques.
WO2006103657A3 (fr) Composition solide de distribution intra-buccale d'insuline
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina